IMV Price/Sales
What is the Price/Sales of IMV?
The Price/Sales of IMV, Inc. is 42,464.98
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on TSX compared to IMV
What does IMV do?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Companies with price/sales similar to IMV
- Trend Innovations has Price/Sales of 33,427.20
- Sustainable Power Infra Split C has Price/Sales of 34,350.49
- Shiva Cement has Price/Sales of 34,990.57
- Cannon Resources Ltd has Price/Sales of 38,244.89
- Eidos Therapeutics Inc has Price/Sales of 39,313.66
- Bluejay Mining Plc has Price/Sales of 40,781.35
- IMV has Price/Sales of 42,464.98
- Trillium Therapeutics has Price/Sales of 44,312.87
- Trillium Therapeutics Inc has Price/Sales of 45,025.77
- Cielo Waste Solutions Corp has Price/Sales of 49,790.10
- Allogene Therapeutics Inc has Price/Sales of 53,151.74
- De Grey Mining has Price/Sales of 54,861.26
- Clime Investment Management has Price/Sales of 55,351.98